PictorLabs, a cutting-edge software company transforming the field of histopathology with its AI-driven virtual staining technology, has announced the successful close of its $30 million Series B funding round. Led by global software investor Insight Partners, the round also saw continued support from M Ventures, the venture capital arm of Merck KGaA, Darmstadt, Germany, which led PictorLabs’ previous Series A round.
The new funding will help PictorLabs accelerate its technological advancements, grow its market presence, and drive the adoption of its virtual staining technology in clinical and research environments.
Founded as a spinoff from UCLA’s Colleges of Engineering and Medicine, PictorLabs is revolutionizing a 150-year-old practice in histological staining—a vital technique used in diagnosing cancer, infectious diseases, and other medical conditions. Traditional methods of staining involve the use of toxic reagents and can take hours or even days to produce results. PictorLabs’ innovative approach, which leverages AI to create virtual stains, eliminates the need for these reagents and reduces turnaround time to mere minutes. As the demand for faster, more efficient diagnostic tools increases, PictorLabs is set to play a key role in the digital transformation of pathology labs worldwide.
“This Series B funding represents a significant endorsement of our technology and our mission to reshape the field of histopathology,” said Yair Rivenson, CEO of PictorLabs. “With this capital, we will be able to scale our operations, expand our talented team, and bring our AI-powered virtual staining technology to more laboratories globally, ultimately enhancing patient outcomes.”
Revolutionizing Histopathology
PictorLabs’ AI-powered virtual staining technology is poised to bring unprecedented speed and accuracy to the pathology field. Traditional staining techniques, which require chemical reagents and manual processes, are labor-intensive and subject to variability. In contrast, PictorLabs’ virtual staining technology delivers consistent, high-quality results in a fraction of the time. This innovation not only accelerates diagnosis but also reduces reliance on toxic chemicals, contributing to more sustainable lab operations.
The platform’s ability to produce virtually unlimited tests from a single tissue sample enables physicians and researchers to gather more comprehensive data in less time. By streamlining this critical process, PictorLabs is helping pathologists make more informed, timely decisions that can lead to better patient care.
Investor Confidence and Market Potential
Scott Barclay, Managing Director at Insight Partners, praised the potential impact of PictorLabs’ technology. “By digitizing the staining process, PictorLabs is improving the speed, consistency, and quality of pathology reports. This innovation will benefit both patient care and life science research,” said Barclay. “We are proud to support Yair and his dedicated team as they continue to push the boundaries of science with validated, data-driven technology that has the potential to revolutionize the field.”
M Ventures, a returning investor, also expressed confidence in PictorLabs’ trajectory. “We remain excited by PictorLabs’ progress and are continually impressed by the distinctiveness of their virtual staining technology,” said Bauke Anninga, Investment Director at M Ventures. “We look forward to supporting the company in its next phase of growth as it continues to scale.”
A New Era in Diagnostic Testing
PictorLabs’ virtual staining solution is not only speeding up the diagnostic process but also enabling researchers to extract greater insights from tissue samples. The ability to run multiple tests on a single specimen without degradation ensures that pathologists can obtain a more thorough understanding of the condition being examined. This comprehensive approach to tissue analysis offers physicians and researchers a new level of diagnostic confidence.
As demand for faster, more accurate diagnostic tools continues to grow in the medical and research communities, PictorLabs is well-positioned to meet the evolving needs of pathologists. By reducing time and resource consumption, the company is also supporting efforts to make laboratory practices more efficient and sustainable.
Paving the Way for Global Adoption
With its Series B funding in place, PictorLabs is set to accelerate its technology development and expand its market reach. The company’s virtual staining platform has already demonstrated its ability to significantly reduce diagnostic turnaround times while maintaining the quality and accuracy required in medical and research settings.
PictorLabs’ AI-powered approach is paving the way for the future of pathology, offering a faster, more sustainable alternative to traditional staining methods. With strong backing from industry-leading investors and continued advancements in AI-driven diagnostics, PictorLabs is on track to revolutionize the field of histopathology.
Tags: PictorLabs, PictorLabs $30M, PictorLabs Funding, PictorLabs Series B, PictorLabs Funding
